The available fluoropyrimidines and oxaliplatin combinations for colorectal cancer patients
have different safety profiles. The aim of this systematic review was to compare their …

Background Oxaliplatin induces splenomegaly, which can cause blood sequestration and
relevant cytopenia, leading to further dose reductions and schedule modifications of …

Objective A meta‐analysis of randomized controlled trials (RCT) was carried out to
determine the efficacy and safety of capecitabine plus oxaliplatin (CAPOX) or fluorouracil …

Objectives: Irinotecan or oxaliplatin combined with 5-fluorouracil (5-FU)±folinic acid (FA) has
changed the treatment standards for metastatic colorectal cancer (CRC). The oxaliplatin and …

3596 Background: The oral fluoropyrimidine X has superior efficacy and improved safety
compared with bolus 5-FU/LV in MCRC. Twice-daily oral X mimics 5-FU infusion and is …

Recent clinical and research development supports the use of 5-fluorouracil in combination
with oxaliplatin for the treatment of patients with advanced colorectal cancer (CRC). 5 …

4029 Background: X has comparable efficacy, safety and convenience benefits over 5-
FU/LV (Mayo clinic) in adjuvant colon cancer and first-line MCRC. A recent phase III trial in …

The medical treatment of colorectal cancer (CRC) has rapidly evolved in recent years with
the introduction of novel cytotoxic drugs into clinical practice such as irinotecan, oxaliplatin …

3507 Background: The use of adjuvant chemotherapy in patients (pts) with stage II colon
cancer who lack “high-risk” features ([HiR] perforation, T4 disease and/or less than 12 lymph …

Background 5-fluorouracil (5-FU) was the standard treatment care for colorectal cancer
(CRC), however, its efficacy was limited due to safety concerns. Capecitabine and …